Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY03003 in Early Primary Parkinson's Disease
NCT04571164Phase 3Completed
- Sponsor
- Luye Pharma Group
- Start
- May 2020
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rotigotine in Parkinson's disease (PD) (2 arms), sponsored by Luye Pharma Group. Primary endpoint: Change from baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part II+III Total Score at 24 weeks. Started May 2020; status: completed.
02
Drugs
rotigotine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04571164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04571164.